Can nitric oxide-based therapy prevent bronchopulmonary dysplasia?

Clinics in Perinatology

Volumn 39, Issue 3, 2012, Pages 613-638

  Raffay, Thomas M ^a   Martin, Richard J ^a   Reynolds, James D ^b,c  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Bronchopulmonary dysplasia (BPD); Ethyl nitrite (ENO); Inhaled nitric oxide (iNO); Neonate; Prematurity; S nitrosothiol (SNO); S nitrosylation

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; ETHYL NITRITE; GLYCERYL TRINITRATE; INDUCIBLE NITRIC OXIDE SYNTHASE; LUNG SURFACTANT; NEURONAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; NITRITE; NITROPRUSSIDE SODIUM; S NITROSOTHIOL; STEROID; UNCLASSIFIED DRUG;

ARTIFICIAL VENTILATION; CHRONIC LUNG DISEASE; DISEASE SEVERITY; DRUG DOSE TITRATION; ENZYME ACTIVITY; HUMAN; INFANT MORTALITY; INFLAMMATION; INTRACELLULAR SIGNALING; LOW DRUG DOSE; LUNG DEVELOPMENT; LUNG DYSPLASIA; LUNG FUNCTION; LUNG VENTILATION; NATIONAL HEALTH ORGANIZATION; NITRIC OXIDE THERAPY; NITROSYLATION; NONHUMAN; OUTCOME ASSESSMENT; OXYGENATION; PREMATURITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; REVIEW; RISK ASSESSMENT; THERAPY;

ADMINISTRATION, INHALATION; ANIMALS; BRONCHOPULMONARY DYSPLASIA; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; NITRIC OXIDE; PRACTICE GUIDELINES AS TOPIC;

EID: 84865782588     PISSN: 00955108     EISSN: 15579840     Source Type: Journal    
DOI: 10.1016/j.clp.2012.06.011     Document Type: Review

References (149)

1. Northway W.H., Rosan R.C., Porter D.Y. Pulmonary disease following respirator therapy of hyaline-membrane disease. Bronchopulmonary dysplasia. N Engl J Med 1967, 276:357-368.
2. Fanaroff A.A., Stoll B.J., Wright L.L., et al. Trends in neonatal morbidity and mortality for very low birthweight infants. Am J Obstet Gynecol 2007, 196(147):e1-e8.
3. D'Angio C.T., Maniscalco W.M. Bronchopulmonary dysplasia in preterm infants: pathophysiology and management strategies. Paediatr Drugs 2004, 6:303-330.
4. Gien J., Kinsella J.P. Pathogenesis and treatment of bronchopulmonary dysplasia. Curr Opin Pediatr 2011, 23:305-313.
5. Bancalari E., Polin R.A. The newborn lung 2008, Saunders/Elsevier, Philadelphia. 1st edition.
6. Baraldi E., Filippone M. Chronic lung disease after premature birth. N Engl J Med 2007, 357:1946-1955.
7. Jobe A.H., Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med 2001, 163:1723-1729.
8. Cole F.S., Alleyne C., Barks J.D., et al. NIH Consensus Development Conference statement: inhaled nitric-oxide therapy for premature infants. Pediatrics 2011, 127:363-369.
9. Northway W.H., Moss R.B., Carlisle K.B., et al. Late pulmonary sequelae of bronchopulmonary dysplasia. N Engl J Med 1990, 323:1793-1799.
10. Trachsel D., Brutsche M.H., Hug-Batschelet H., et al. Progressive static pulmonary hyperinflation in survivors of severe bronchopulmonary dysplasia by mid-adulthood. Thorax 2011, [Epub ahead of print].
11. Frostell C., Fratacci M.D., Wain J.C., et al. Inhaled nitric oxide. A selective pulmonary vasodilator reversing hypoxic pulmonary vasoconstriction. Circulation 1991, 83:2038-2047.
12. Roberts J.D., Polaner D.M., Lang P., et al. Inhaled nitric oxide in persistent pulmonary hypertension of the newborn. Lancet 1992, 340:818-819.
13. Kinsella J.P., Neish S.R., Shaffer E., et al. Low-dose inhalation nitric oxide in persistent pulmonary hypertension of the newborn. Lancet 1992, 340:819-820.
14. Inhaled nitric oxide in full-term and nearly full-term infants with hypoxic respiratory failure. The Neonatal Inhaled Nitric Oxide Study Group. N Engl J Med 1997, 336:597-604.
15. Clark R.H., Kueser T.J., Walker M.W., et al. Low-dose nitric oxide therapy for persistent pulmonary hypertension of the newborn. Clinical Inhaled Nitric Oxide Research Group. N Engl J Med 2000, 342:469-474.
16. Davidson D., Barefield E.S., Kattwinkel J., et al. Inhaled nitric oxide for the early treatment of persistent pulmonary hypertension of the term newborn: a randomized, double-masked, placebo-controlled, dose-response, multicenter study. The I-NO/PPHN Study Group. Pediatrics 1998, 101:325-334.
17. McCurnin D.C., Pierce R.A., Chang L.Y., et al. Inhaled NO improves early pulmonary function and modifies lung growth and elastin deposition in a baboon model of neonatal chronic lung disease. Am J Physiol Lung Cell Mol Physiol 2005, 288:L450-L459.
18. Iben S.C., Dreshaj I.A., Farver C.F., et al. Role of endogenous nitric oxide in hyperoxia-induced airway hyperreactivity in maturing rats. J Applied Physiology 2000, 89:1205-1212.
19. Lin Y.J., Markham N.E., Balasubramaniam V., et al. Inhaled nitric oxide enhances distal lung growth after exposure to hyperoxia in neonatal rats. Pediatr Res 2005, 58:22-29.
20. Bland R.D., Albertine K.H., Carlton D.P., et al. Inhaled nitric oxide effects on lung structure and function in chronically ventilated preterm lambs. Am J Respir Crit Care Med 2005, 172:899-906.
21. Early compared with delayed inhaled nitric oxide in moderately hypoxaemic neonates with respiratory failure: a randomised controlled trial. The Franco-Belgium Collaborative NO Trial Group. Lancet 1999, 354:1066-1071.
22. Ballard R.A., Truog W.E., Cnaan A., et al. Inhaled nitric oxide in preterm infants undergoing mechanical ventilation. N Engl J Med 2006, 355:343-353.
23. Dani C., Bertini G., Pezzati M., et al. Inhaled nitric oxide in very preterm infants with severe respiratory distress syndrome. Acta Paediatr 2006, 95:1116-1123.
24. Field D., Elbourne D., Truesdale A., et al. Neonatal ventilation with inhaled nitric oxide versus ventilatory support without inhaled nitric oxide for preterm infants with severe respiratory failure: the INNOVO multicentre randomised controlled trial (ISRCTN 17821339). Pediatrics 2005, 115:926-936.
25. Hascoet J.M., Fresson J., Claris O., et al. The safety and efficacy of nitric oxide therapy in premature infants. J Pediatr 2005, 146:318-323.
26. Kinsella J.P., Cutter G.R., Walsh W.F., et al. Early inhaled nitric oxide therapy in premature newborns with respiratory failure. N Engl J Med 2006, 355:354-364.
27. Kinsella J.P., Walsh W.F., Bose C.L., et al. Inhaled nitric oxide in premature neonates with severe hypoxaemic respiratory failure: a randomised controlled trial. Lancet 1999, 354:1061-1065.
28. Mercier J.C., Hummler H., Durrmeyer X., et al. Inhaled nitric oxide for prevention of bronchopulmonary dysplasia in premature babies (EUNO): a randomised controlled trial. Lancet 2010, 376:346-354.
29. Schreiber M.D., Gin-Mestan K., Marks J.D., et al. Inhaled nitric oxide in premature infants with the respiratory distress syndrome. N Engl J Med 2003, 349:2099-2107.
30. Srisuparp P., Heitschmidt M., Schreiber M.D. Inhaled nitric oxide therapy in premature infants with mild to moderate respiratory distress syndrome. J Med Assoc Thai 2002, 85(Suppl 2):S469-S478.
31. Su P.H., Chen J.Y. Inhaled nitric oxide in the management of preterm infants with severe respiratory failure. J Perinatol 2008, 28:112-116.
32. Subhedar N.V., Ryan S.W., Shaw N.J. Open randomised controlled trial of inhaled nitric oxide and early dexamethasone in high risk preterm infants. Arch Dis Child Fetal Neonatal Ed 1997, 77:F185-F190.
33. Van Meurs K.P., Hintz S.R., Ehrenkranz R.A., et al. Inhaled nitric oxide in infants >1500 g and <34 weeks gestation with severe respiratory failure. J Perinatol 2007, 27:347-352.
34. Van Meurs K.P., Wright L.L., Ehrenkranz R.A., et al. Inhaled nitric oxide for premature infants with severe respiratory failure. N Engl J Med 2005, 353:13-22.
35. Barrington K.J., Finer N. Inhaled nitric oxide for respiratory failure in preterm infants. Cochrane Database Syst Rev 2010, 12. CD000509.
36. Askie L.M., Ballard R.A., Cutter G.R., et al. Inhaled nitric oxide in preterm infants: an individual-patient data meta-analysis of randomized trials. Pediatrics 2011, 128:729-739.
37. Donohue P.K., Gilmore M.M., Cristofalo E., et al. Inhaled nitric oxide in preterm infants: a systematic review. Pediatrics 2011, 127:e414-e422.
38. Hibbs A.M., Walsh M.C., Martin R.J., et al. One-year respiratory outcomes of preterm infants enrolled in the Nitric Oxide (to prevent) Chronic Lung Disease trial. J Pediatr 2008, 153:525-529.
39. Walsh M.C., Hibbs A.M., Martin C.R., et al. Two-year neurodevelopmental outcomes of ventilated preterm infants treated with inhaled nitric oxide. J Pediatr 2010, 156:556-561.e1.
40. Watson R.S., Clermont G., Kinsella J.P., et al. Clinical and economic effects of iNO in premature newborns with respiratory failure at 1 year. Pediatrics 2009, 124:1333-1343.
41. Hamon I., Fresson J., Nicolas M.B., et al. Early inhaled nitric oxide improves oxidative balance in very preterm infants. Pediatr Res 2005, 57:637-643.
42. Huddy C.L., Bennett C.C., Hardy P., et al. The INNOVO multicentre randomised controlled trial: neonatal ventilation with inhaled nitric oxide versus ventilatory support without nitric oxide for severe respiratory failure in preterm infants: follow up at 4-5 years. Arch Dis Child Fetal Neonatal Ed 2008, 93:F430-F435.
43. Hintz S.R., Van Meurs K.P., Perritt R., et al. Neurodevelopmental outcomes of premature infants with severe respiratory failure enrolled in a randomized controlled trial of inhaled nitric oxide. J Pediatr 2007, 151:16-22. e1-3.
44. Mestan K.K., Marks J.D., Hecox K., et al. Neurodevelopmental outcomes of premature infants treated with inhaled nitric oxide. N Engl J Med 2005, 353:23-32.
45. Bennett A.J., Shaw N.J., Gregg J.E., et al. Neurodevelopmental outcome in high-risk preterm infants treated with inhaled nitric oxide. Acta Paediatr 2001, 90:573-576.
46. Tanaka Y., Hayashi T., Kitajima H., et al. Inhaled nitric oxide therapy decreases the risk of cerebral palsy in preterm infants with persistent pulmonary hypertension of the newborn. Pediatrics 2007, 119:1159-1164.
47. Steinhorn R.H., Shaul P.W., deRegnier R.A., et al. Inhaled nitric oxide and bronchopulmonary dysplasia. Pediatrics 2011, 128:e255-e256. [author reply: e6-7].
48. Lima B., Forrester M.T., Hess D.T., et al. S-Nitrosylation in cardiovascular signaling. Circ Res 2010, 106:633-646.
49. Hess D.T., Foster M.W., Stamler J.S. Assays for S-nitrosothiols and S-nitrosylated proteins and mechanistic insights into cardioprotection. Circulation 2009, 120:190-193.
50. Martin R.J., Walsh M.C. Inhaled nitric oxide for preterm infants-who benefits?. N Engl J Med 2005, 353:82-84.
51. Khan S.A., Lee K., Minhas K.M., et al. Neuronal nitric oxide synthase negatively regulates xanthine oxidoreductase inhibition of cardiac excitation-contraction coupling. Proc Natl Acad Sci U S A 2004, 101:15944-15948.
52. Saavedra W.F., Paolocci N., St John M.E., et al. Imbalance between xanthine oxidase and nitric oxide synthase signaling pathways underlies mechanoenergetic uncoupling in the failing heart. Circ Res 2002, 90:297-304.
53. Landmesser U., Spiekermann S., Dikalov S., et al. Vascular oxidative stress and endothelial dysfunction in patients with chronic heart failure: role of xanthine-oxidase and extracellular superoxide dismutase. Circulation 2002, 106:3073-3078.
54. Hilenski L.L., Clempus R.E., Quinn M.T., et al. Distinct subcellular localizations of Nox1 and Nox4 in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2004, 24:677-683.
55. Foster M.W., Hess D.T., Stamler J.S. Protein S-nitrosylation in health and disease: a current perspective. Trends Mol Med 2009, 15:391-404.
56. Wei W., Li B., Hanes M.A., et al. S-Nitrosylation from GSNOR deficiency impairs DNA repair and promotes hepatocarcinogenesis. Sci Transl Med 2010, 2:19ra3.
57. Prasad R., Giri S., Nath N., et al. GSNO attenuates EAE disease by S-nitrosylation-mediated modulation of endothelial-monocyte interactions. Glia 2007, 55:65-77.
58. Savidge T.C., Newman P., Pothoulakis C., et al. Enteric glia regulate intestinal barrier function and inflammation via release of S-nitrosoglutathione. Gastroenterology 2007, 132:1344-1358.
59. Auten R.L., Mason S.N., Whorton M.H., et al. Inhaled ethyl nitrite prevents hyperoxia-impaired postnatal alveolar development in newborn rats. Am J Respir Crit Care Med 2007, 176:291-299.
60. Marshall H.E., Potts E.N., Kelleher Z.T., et al. Protection from lipopolysaccharide-induced lung injury by augmentation of airway S-nitrosothiols. Am J Respir Crit Care Med 2009, 180:11-18.
61. Que L.G., Liu L., Yan Y., et al. Protection from experimental asthma by an endogenous bronchodilator. Science 2005, 308:1618-1621.
62. Snyder A.H., McPherson M.E., Hunt J.F., et al. Acute effects of aerosolized S-nitrosoglutathione in cystic fibrosis. Am J Respir Crit Care Med 2002, 165:922-926.
63. Gaston B., Singel D., Doctor A., et al. S-Nitrosothiol signaling in respiratory biology. Am J Respir Crit Care Med 2006, 173:1186-1193.
64. Daaka Y. S-Nitrosylation-regulated GPCR signaling. Biochim Biophys Acta 2012, 1820(6):743-751.
65. Seth D., Stamler J.S. The SNO-proteome: causation and classifications. Curr Opin Chem Biol 2011, 15:129-136.
66. Hess D.T., Stamler J.S. Regulation by S-nitrosylation of protein post-translational modification. J Biol Chem 2012, 287:4411-4418.
67. Schulman I.H., Hare J.M. Regulation of cardiovascular cellular processes by S-nitrosylation. Biochim Biophys Acta 2012, 1820(6):752-762.
68. Grasemann H., Gaston B., Fang K., et al. Decreased levels of nitrosothiols in the lower airways of patients with cystic fibrosis and normal pulmonary function. J Pediatr 1999, 135:770-772.
69. Zaman K., Carraro S., Doherty J., et al. S-Nitrosylating agents: a novel class of compounds that increase cystic fibrosis transmembrane conductance regulator expression and maturation in epithelial cells. Mol Pharmacol 2006, 70:1435-1442.
70. Gaston B., Sears S., Woods J., et al. Bronchodilator S-nitrosothiol deficiency in asthmatic respiratory failure. Lancet 1998, 351:1317-1319.
71. Que L.G., Yang Z., Stamler J.S., et al. S-Nitrosoglutathione reductase: an important regulator in human asthma. Am J Respir Crit Care Med 2009, 180:226-231.
72. McMahon T.J., Ahearn G.S., Moya M.P., et al. A nitric oxide processing defect of red blood cells created by hypoxia: deficiency of S-nitrosohemoglobin in pulmonary hypertension. Proc Natl Acad Sci U S A 2005, 102:14801-14806.
73. Singel D.J., Stamler J.S. Chemical physiology of blood flow regulation by red blood cells: the role of nitric oxide and S-nitrosohemoglobin. Annu Rev Physiol 2005, 67:99-145.
74. Doctor A., Stamler J.S. Nitric oxide transport in blood: a third gas in the respiratory cycle. Comprehensive Physiology 2011, 541-568. John Wiley & Sons, Inc.
75. Luchsinger B.P., Rich E.N., Gow A.J., et al. Routes to S-nitroso-hemoglobin formation with heme redox and preferential reactivity in the beta subunits. Proc Natl Acad Sci U S A 2003, 100:461-466.
76. Angelo M., Singel D.J., Stamler J.S. An S-nitrosothiol (SNO) synthase function of hemoglobin that utilizes nitrite as a substrate. Proc Natl Acad Sci U S A 2006, 103:8366-8371.
77. Pezacki J.P., Ship N.J., Kluger R. Release of nitric oxide from S-nitrosohemoglobin. Electron transfer as a response to deoxygenation. J Am Chem Soc 2001, 123:4615-4616.
78. McMahon T.J., Stone A.E., Bonaventura J., et al. Functional coupling of oxygen binding and vasoactivity in S-nitrosohemoglobin. J Biol Chem 2000, 275:16738-16745.
79. Doctor A., Platt R., Sheram M.L., et al. Hemoglobin conformation couples erythrocyte S-nitrosothiol content to O2 gradients. Proc Natl Acad Sci U S A 2005, 102:5709-5714.
80. Deem S., Min J.H., Moulding J.D., et al. Red blood cells prevent inhibition of hypoxic pulmonary vasoconstriction by nitrite in isolated, perfused rat lungs. Am J Physiol Heart Circ Physiol 2007, 292:H963-H970.
81. Hodges A.N., Delaney S., Lecomte J.M., et al. Effect of hyperbaric oxygen on oxygen uptake and measurements in the blood and tissues in a normobaric environment. Br J Sports Med 2003, 37:516-520.
82. Duling B.R., Berne R.M. Longitudinal gradients in periarteriolar oxygen tension. A possible mechanism for the participation of oxygen in local regulation of blood flow. Circ Res 1970, 27:669-678.
83. Allen B.W., Stamler J.S., Piantadosi C.A. Hemoglobin, nitric oxide and molecular mechanisms of hypoxic vasodilation. Trends Mol Med 2009, 15:452-460.
84. Intaglietta M., Johnson P.C., Winslow R.M. Microvascular and tissue oxygen distribution. Cardiovasc Res 1996, 32:632-643.
85. Roach R.C., Koskolou M.D., Calbet J.A., et al. Arterial O2 content and tension in regulation of cardiac output and leg blood flow during exercise in humans. Am J Physiol 1999, 276:H438-H445.
86. Gonzalez-Alonso J., Olsen D.B., Saltin B. Erythrocyte and the regulation of human skeletal muscle blood flow and oxygen delivery: role of circulating ATP. Circ Res 2002, 91:1046-1055.
87. Gonzalez-Alonso J., Mortensen S.P., Dawson E.A., et al. Erythrocytes and the regulation of human skeletal muscle blood flow and oxygen delivery: role of erythrocyte count and oxygenation state of haemoglobin. J Physiol 2006, 572:295-305.
88. McMahon T.J., Moon R.E., Luschinger B.P., et al. Nitric oxide in the human respiratory cycle. Nat Med 2002, 8:711-717.
89. Schroeder R.A., Cai C., Kuo P.C. Endotoxin-mediated nitric oxide synthesis inhibits IL-1beta gene transcription in ANA-1 murine macrophages. Am J Physiol 1999, 277:C523-C530.
90. Xiong H., Zhu C., Li F., et al. Inhibition of interleukin-12 p40 transcription and NF-kappaB activation by nitric oxide in murine macrophages and dendritic cells. J Biol Chem 2004, 279:10776-10783.
91. Into T., Inomata M., Nakashima M., et al. Regulation of MyD88-dependent signaling events by S nitrosylation retards toll-like receptor signal transduction and initiation of acute-phase immune responses. Mol Cell Biol 2008, 28:1338-1347.
92. del Fresno C., Gomez-Garcia L., Caveda L., et al. Nitric oxide activates the expression of IRAK-M via the release of TNF-alpha in human monocytes. Nitric Oxide 2004, 10:213-220.
93. Gonzalez-Leon M.C., Soares-Schanoski A., del Fresno C., et al. Nitric oxide induces SOCS-1 expression in human monocytes in a TNF-alpha-dependent manner. J Endotoxin Res 2006, 12:296-306.
94. Marshall H.E., Stamler J.S. Inhibition of NF-kappa B by S-nitrosylation. Biochemistry 2001, 40:1688-1693.
95. Kelleher Z.T., Matsumoto A., Stamler J.S., et al. NOS2 regulation of NF-kappaB by S-nitrosylation of p65. J Biol Chem 2007, 282:30667-30672.
96. Guo C.J., Atochina-Vasserman E.N., Abramova E., et al. S-Nitrosylation of surfactant protein-D controls inflammatory function. PLoS Biol 2008, 6:e266.
97. Park H.S., Huh S.H., Kim M.S., et al. Nitric oxide negatively regulates c-Jun N-terminal kinase/stress-activated protein kinase by means of S-nitrosylation. Proc Natl Acad Sci U S A 2000, 97:14382-14387.
98. Kim S.F., Huri D.A., Snyder S.H. Inducible nitric oxide synthase binds, S-nitrosylates, and activates cyclooxygenase-2. Science 2005, 310:1966-1970.
99. Thompson A., Bhandari V. Pulmonary biomarkers of bronchopulmonary dysplasia. Biomark Insights 2008, 3:361-373.
100. Schwarz M.A., Cleaver O.B. Development of the pulmonary endothelium in development of the pulmonary circulation: vasculogenesis and angiogenesis. The pulmonary endothelium: function in health and disease 2009, 24. John Wiley, Hoboken (NJ). N.F. Voelkel, S. Rounds (Eds.).
101. Husain A.N., Siddiqui N.H., Stocker J.T. Pathology of arrested acinar development in postsurfactant bronchopulmonary dysplasia. Hum Pathol 1998, 29:710-717.
102. Pardi G., Cetin I., Marconi A.M., et al. Diagnostic value of blood sampling in fetuses with growth retardation. N Engl J Med 1993, 328:692-696.
103. Gao Y., Raj J.U. Regulation of the pulmonary circulation in the fetus and newborn. Physiol Rev 2010, 90:1291-1335.
104. Ahlfeld S.K., Conway S.J. Aberrant signaling pathways of the lung mesenchyme and their contributions to the pathogenesis of bronchopulmonary dysplasia. Birth Defects Res A Clin Mol Teratol 2012, 94:3-15.
105. Sheffield M., Mabry S., Thibeault D.W., et al. Pulmonary nitric oxide synthases and nitrotyrosine: findings during lung development and in chronic lung disease of prematurity. Pediatrics 2006, 118:1056-1064.
106. Davis C.W., Gonzales L.W., Ballard R.A., et al. Expression of nitric oxide synthases and endogenous NO metabolism in bronchopulmonary dysplasia. Pediatr Pulmonol 2008, 43:703-709.
107. Gow A.J., Chen Q., Hess D.T., et al. Basal and stimulated protein S-nitrosylation in multiple cell types and tissues. J Biol Chem 2002, 277:9637-9640.
108. Abman S.H. Impaired vascular endothelial growth factor signaling in the pathogenesis of neonatal pulmonary vascular disease. Adv Exp Med Biol 2010, 661:323-335.
109. Bhatt A.J., Pryhuber G.S., Huyck H., et al. Disrupted pulmonary vasculature and decreased vascular endothelial growth factor, Flt-1, and TIE-2 in human infants dying with bronchopulmonary dysplasia. Am J Respir Crit Care Med 2001, 164:1971-1980.
110. Hasan J., Beharry K.D., Valencia A.M., et al. Soluble vascular endothelial growth factor receptor 1 in tracheal aspirate fluid of preterm neonates at birth may be predictive of bronchopulmonary dysplasia/chronic lung disease. Pediatrics 2009, 123:1541-1547.
111. Popova A.P., Bozyk P.D., Bentley J.K., et al. Isolation of tracheal aspirate mesenchymal stromal cells predicts bronchopulmonary dysplasia. Pediatrics 2010, 126:e1127-e1133.
112. De Paepe M.E., Patel C., Tsai A., et al. Endoglin (CD105) up-regulation in pulmonary microvasculature of ventilated preterm infants. Am J Respir Crit Care Med 2008, 178:180-187.
113. Fujinaga H., Baker C.D., Ryan S.L., et al. Hyperoxia disrupts vascular endothelial growth factor-nitric oxide signaling and decreases growth of endothelial colony-forming cells from preterm infants. Am J Physiol Lung Cell Mol Physiol 2009, 297:L1160-L1169.
114. Ohls R.K. Transfusions in the preterm infant. Neoreviews 2007, 8:e377-e386.
115. Nunes dos Santos A.M., Trindade C.E. Red blood cell transfusions in the neonate. Neoreviews 2011, 12:e13-e19.
116. Cooke R.W., Drury J.A., Yoxall C.W., et al. Blood transfusion and chronic lung disease in preterm infants. Eur J Pediatr 1997, 156:47-50.
117. Valieva O.A., Strandjord T.P., Mayock D.E., et al. Effects of transfusions in extremely low birth weight infants: a retrospective study. J Pediatr 2009, 155:331-337.e1.
118. Zhang H., Fang J., Su H., et al. Risk factors for bronchopulmonary dysplasia in neonates born at ≤1500 g (1999-2009). Pediatr Int 2011, 53:915-920.
119. Reynolds J.D., Ahearn G.S., Angelo M., et al. S-Nitrosohemoglobin deficiency: a mechanism for loss of physiological activity in banked blood. Proc Natl Acad Sci U S A 2007, 104:17058-17062.
120. Reynolds J.D., Hess D.T., Stamler J.S. The transfusion problem: role of aberrant S-nitrosylation. Transfusion 2011, 51:852-858.
121. Murad F. Shattuck Lecture. Nitric oxide and cyclic GMP in cell signaling and drug development. N Engl J Med 2006, 355:2003-2011.
122. Elrod J.W., Calvert J.W., Gundewar S., et al. Nitric oxide promotes distant organ protection: evidence for an endocrine role of nitric oxide. Proc Natl Acad Sci U S A 2008, 105:11430-11435.
123. Fox-Robichaud A., Payne D., Hasan S.U., et al. Inhaled NO as a viable antiadhesive therapy for ischemia/reperfusion injury of distal microvascular beds. J Clin Invest 1998, 101:2497-2505.
124. Ibrahim Y.I., Ninnis J.R., Hopper A.O., et al. Inhaled nitric oxide therapy increases blood nitrite, nitrate, and s-nitrosohemoglobin concentrations in infants with pulmonary hypertension. J Pediatr 2012, 160:245-251.
125. Minamishima S., Kida K., Tokuda K., et al. Inhaled nitric oxide improves outcomes after successful cardiopulmonary resuscitation in mice. Circulation 2011, 124:1645-1653.
126. Ng E.S., Jourd'heuil D., McCord J.M., et al. Enhanced S-nitroso-albumin formation from inhaled NO during ischemia/reperfusion. Circ Res 2004, 94:559-565.
127. Top A.P., Ince C., Schouwenberg P.H., et al. Inhaled nitric oxide improves systemic microcirculation in infants with hypoxemic respiratory failure. Pediatr Crit Care Med 2011, 12:e271-e274.
128. Terpolilli N.A., Kim S.W., Thal S.C., et al. Inhalation of nitric oxide prevents ischemic brain damage in experimental stroke by selective dilatation of collateral arterioles. Circ Res 2012, 110(5):727-738.
129. McMahon T.J., Doctor A. Extrapulmonary effects of inhaled nitric oxide: role of reversible S-nitrosylation of erythrocytic hemoglobin. Proc Am Thorac Soc 2006, 3:153-160.
130. Wind M., Stern A. Comparison of human adult and fetal hemoglobin: aminophenol-induced methemoglobin formation. Experientia 1977, 33:1500-1501.
131. Farrow K.N., Groh B.S., Schumacker P.T., et al. Hyperoia increases phosphodiesterase 5 expression and activity in ovine fetal pulmonary artery smooth muscle cells. Circ Res 2008, 102:226-233.
132. Ali N.K., Jafri A., Sopi R.B., et al. Role of arginase in impairing relaxation of lung parenchyma of hyperoxia-exposed neonatal rats. Neonatology 2012, 101:106-115.
133. Janero D.R., Bryan N.S., Saijo F., et al. Differential nitros(yl)ation of blood and tissue constituents during glyceryl trinitrate biotransformation in vivo. Proc Natl Acad Sci U S A 2004, 101:16958-16963.
134. Schutte H., Grimminger F., Otterbein J., et al. Efficiency of aerosolized nitric oxide donor drugs to achieve sustained pulmonary vasodilation. J Pharmacol Exp Ther 1997, 282:985-994.
135. Brunton T.L. On the employment of nitrite of amyl in the collapse of cholera. Br Med J 1872, 1:42-45.
136. Palhares D.B., Figueiredo C.S., Moura A.J. Endotracheal inhalatory sodium nitroprusside in severely hypoxic newborns. J Perinat Med 1998, 26:219-224.
137. Goyal P., Kiran U., Chauhan S., et al. Efficacy of nitroglycerin inhalation in reducing pulmonary arterial hypertension in children with congenital heart disease. Br J Anaesth 2006, 97:208-214.
138. Bando M., Ishii Y., Kitamura S., et al. Effects of inhalation of nitroglycerin on hypoxic pulmonary vasoconstriction. Respiration 1998, 65:63-70.
139. Moya M.P., Gow A.J., McMahon T.J., et al. S-Nitrosothiol repletion by an inhaled gas regulates pulmonary function. Proc Natl Acad Sci U S A 2001, 98:5792-5797.
140. Jia L., Bonaventura C., Bonaventura J., et al. S-Nitrosohaemoglobin: a dynamic activity of blood involved in vascular control. Nature 1996, 380:221-226.
141. Lima B., Lam G.K., Xie L., et al. Endogenous S-nitrosothiols protect against myocardial injury. Proc Natl Acad Sci U S A 2009, 106:6297-6302.
142. Ali N.A., Eubanks W.S., Stamler J.S., et al. A method to attenuate pneumoperitoneum-induced reductions in splanchnic blood flow. Ann Surg 2005, 241:256-261.
143. Shimazutsu K., Uemura K., Auten K.M., et al. Inclusion of a nitric oxide congener in the insufflation gas repletes S-nitrosohemoglobin and stabilizes physiologic status during prolonged carbon dioxide pneumoperitoneum. Clin Transl Sci 2009, 2:405-412.
144. Sheng H., Reynolds J.D., Auten R.L., et al. Pharmacologically augmented S-nitrosylated hemoglobin improves recovery from murine subarachnoid hemorrhage. Stroke 2011, 42:471-476.
145. Moya M.P., Gow A.J., Califf R.M., et al. Inhaled ethyl nitrite gas for persistent pulmonary hypertension of the newborn. Lancet 2002, 360:141-143.
146. Inhaled nitric oxide and neuroprotection in premature infants (NOVA2). Available at: . Accessed December 16, 2011. http://clinicaltrials.gov/ct2/show/NCT00515281.
147. Examining the use of non-invasive inhaled nitric oxide to reduce chronic lung disease in premature newborns. Available at: . Accessed December 16, 2011. http://clinicaltrials.gov/ct2/show/NCT00955487.
148. Inhaled nitric oxide (INO) for the prevention of bronchopulmonary dysplasia (BPD) in preterm infants. Available at: . Accessed December 16, 2011. http://clinicaltrials.gov/ct2/show/NCT00931632.
149. Trial of late surfactant to prevent BPD: a pilot study in ventilated preterm neonates receiving inhaled nitric oxide (TOLSURF Pilot). Available at: . Accessed December 16, 2011. http://clinicaltrials.gov/ct2/show/NCT00569530.